April 28, 2008 - Researchers at the University of Warwick have found a that the protein E-selectin is a marker for endothelial dysfunction and sub-clinical systemic inflammation, which can help identify a far greater number of people at high risk for future development of type 2 diabetes.

Medtronic Inc. has expanded its product line to include the OneTouch UltraLink Meter as the new wireless meter exclusively certified by Medtronic designed to wirelessly communicate with Medtronic diabetes management products in the U.S.

This new meter uses wireless technology to transmit glucose readings directly to MiniMed Paradigm insulin pumps and the Guardian REAL-Time Continuous Glucose Monitoring System. This makes bolus dosing more accurate and easier for patients compared to the manual entry of blood glucose readings.

Armstrong Medical will display its Auto-Locking Cart with an optional proximity card reader for quick access at the 2008 AACN show in Chicago.

The multi-function Avant 2120 tabletop pulse oximeter combines Nonin Medical’s PureSAT pulse oximetry technology with fast, motion tolerant oscillometric NIBP.

The company said it can be used for continuous or spot-check monitoring. The Avant 2120 simultaneously measures, displays and records SPO2, pulse rate and blood pressure for patients pediatric to adult. Its compact, lightweight design makes it a highly mobile and convenient solution for hospital/sub-acute environments.

April 25, 2008 - EPIX Pharmaceuticals Inc. met all pre-specified endpoints prospectively agreed to with the FDA in a blinded, independent re-read of images of its novel blood pool magnetic resonance angiographic (MRA) agent, Vasovist (gadofosveset trisodium), and plans to resubmit a New Drug Application (NDA) to the FDA for Vasovist in mid-2008.

April 25, 2008 - The Society for Cardiovascular Angiography and Interventions (SCAI) and the American College of Cardiology (ACC) will return to the traditional individual meeting formats for both the SCAI Annual Scientific Sessions and i2 Summit in 2009, in response to SCAI members' request for more a intimate meeting.

In 2008, SCAI and ACC partnered to hold the SCAI Annual Scientific Sessions in Partnership with ACCi2 Summit (SCAI-ACCi2), held in conjunction with ACC's Annual Scientific Session in Chicago.

April 25, 2008 - CV Therapeutics reported the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) recommended approval of ranolazine in the European Union (EU) for the treatment of chronic angina.

April 25, 2008 - An everolimus-eluting stent compared with a paclitaxel-eluting stent resulted in reduced angiographic late loss, noninferior rates of target vessel failure, and fewer major adverse cardiac events during one-year of follow-up in a recent study published in JAMA.

Gregg W. Stone, M.D. (Columbia University Medical Center and the Cardiovascular Research Foundation, New York) and colleagues aimed to evaluate the safety and efficacy of an everolimus-eluting stent compared with a widely used paclitaxel-eluting stent.

April 24, 2008 - Boston Scientific Corp. completed enrollment in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT), engineered to test whether CRT-Ds can slow the progression of heart failure in heart attack survivors and in those with other forms of impaired heart function.

April 24, 2008 - ProSolv CardioVascular, a FUJIFILM company, will interface its cardiovascular image and information system (CVIIS) with QLAB, 2D and 3D ultrasound quantification tools software from Philips.

Facilities using Philips ultrasound systems will now have access to Philips' QLAB advanced 2D and 3D ultrasound quantification tools within the ProSolv CardioVascular application, designed to deliver efficiency benefits for clinicians and enhancing the accuracy of diagnosis.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now